MTH1 as a chemotherapeutic target: The elephant in the room

Govindi J. Samaranayake, Mai Huynh, Priyamvada Rai

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Many tumors sustain elevated levels of reactive oxygen species (ROS), which drive oncogenic signaling. However, ROS can also trigger anti-tumor responses, such as cell death or senescence, through induction of oxidative stress and concomitant DNA damage. To circumvent the adverse consequences of elevated ROS levels, many tumors develop adaptive responses, such as enhanced redox-protective or oxidatively-generated damage repair pathways. Targeting these enhanced oxidative stress-protective mechanisms is likely to be both therapeutically effective and highly specific to cancer, as normal cells are less reliant on such mechanisms. In this review, we discuss one such stress-protective protein human MutT Homolog1 (MTH1), an enzyme that eliminates 8-oxo-7,8-dihydro-2’-deoxyguanosine triphosphate (8-oxodGTP) through its pyrophosphatase activity, and is found to be elevated in many cancers. Our studies, and subsequently those of others, identified MTH1 inhibition as an effective tumor-suppressive strategy. However, recent studies with the first wave of MTH1 inhibitors have produced conflicting results regarding their cytotoxicity in cancer cells and have led to questions regarding the validity of MTH1 as a chemotherapeutic target. To address the proverbial “elephant in the room” as to whether MTH1 is a bona fide chemotherapeutic target, we provide an overview of MTH1 function in the context of tumor biology, summarize the current literature on MTH1 inhibitors, and discuss the molecular contexts likely required for its efficacy as a therapeutic target.

Original languageEnglish (US)
Article number47
JournalCancers
Volume9
Issue number5
DOIs
StatePublished - May 8 2017

Fingerprint

Neoplasms
Reactive Oxygen Species
Oxidative Stress
Pyrophosphatases
Cell Aging
Heat-Shock Proteins
DNA Damage
Oxidation-Reduction
Cell Death
Enzymes
Therapeutics

Keywords

  • Cancer
  • MTH1
  • MTH1 inhibitors
  • Nucleotide pool
  • Oxidative stress
  • P53
  • RAS oncogene
  • Therapeutic target

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

MTH1 as a chemotherapeutic target : The elephant in the room. / Samaranayake, Govindi J.; Huynh, Mai; Rai, Priyamvada.

In: Cancers, Vol. 9, No. 5, 47, 08.05.2017.

Research output: Contribution to journalReview article

Samaranayake, Govindi J. ; Huynh, Mai ; Rai, Priyamvada. / MTH1 as a chemotherapeutic target : The elephant in the room. In: Cancers. 2017 ; Vol. 9, No. 5.
@article{5b1ab6f1d3b345d195e6402c9e656a10,
title = "MTH1 as a chemotherapeutic target: The elephant in the room",
abstract = "Many tumors sustain elevated levels of reactive oxygen species (ROS), which drive oncogenic signaling. However, ROS can also trigger anti-tumor responses, such as cell death or senescence, through induction of oxidative stress and concomitant DNA damage. To circumvent the adverse consequences of elevated ROS levels, many tumors develop adaptive responses, such as enhanced redox-protective or oxidatively-generated damage repair pathways. Targeting these enhanced oxidative stress-protective mechanisms is likely to be both therapeutically effective and highly specific to cancer, as normal cells are less reliant on such mechanisms. In this review, we discuss one such stress-protective protein human MutT Homolog1 (MTH1), an enzyme that eliminates 8-oxo-7,8-dihydro-2’-deoxyguanosine triphosphate (8-oxodGTP) through its pyrophosphatase activity, and is found to be elevated in many cancers. Our studies, and subsequently those of others, identified MTH1 inhibition as an effective tumor-suppressive strategy. However, recent studies with the first wave of MTH1 inhibitors have produced conflicting results regarding their cytotoxicity in cancer cells and have led to questions regarding the validity of MTH1 as a chemotherapeutic target. To address the proverbial “elephant in the room” as to whether MTH1 is a bona fide chemotherapeutic target, we provide an overview of MTH1 function in the context of tumor biology, summarize the current literature on MTH1 inhibitors, and discuss the molecular contexts likely required for its efficacy as a therapeutic target.",
keywords = "Cancer, MTH1, MTH1 inhibitors, Nucleotide pool, Oxidative stress, P53, RAS oncogene, Therapeutic target",
author = "Samaranayake, {Govindi J.} and Mai Huynh and Priyamvada Rai",
year = "2017",
month = "5",
day = "8",
doi = "10.3390/cancers9050047",
language = "English (US)",
volume = "9",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - MTH1 as a chemotherapeutic target

T2 - The elephant in the room

AU - Samaranayake, Govindi J.

AU - Huynh, Mai

AU - Rai, Priyamvada

PY - 2017/5/8

Y1 - 2017/5/8

N2 - Many tumors sustain elevated levels of reactive oxygen species (ROS), which drive oncogenic signaling. However, ROS can also trigger anti-tumor responses, such as cell death or senescence, through induction of oxidative stress and concomitant DNA damage. To circumvent the adverse consequences of elevated ROS levels, many tumors develop adaptive responses, such as enhanced redox-protective or oxidatively-generated damage repair pathways. Targeting these enhanced oxidative stress-protective mechanisms is likely to be both therapeutically effective and highly specific to cancer, as normal cells are less reliant on such mechanisms. In this review, we discuss one such stress-protective protein human MutT Homolog1 (MTH1), an enzyme that eliminates 8-oxo-7,8-dihydro-2’-deoxyguanosine triphosphate (8-oxodGTP) through its pyrophosphatase activity, and is found to be elevated in many cancers. Our studies, and subsequently those of others, identified MTH1 inhibition as an effective tumor-suppressive strategy. However, recent studies with the first wave of MTH1 inhibitors have produced conflicting results regarding their cytotoxicity in cancer cells and have led to questions regarding the validity of MTH1 as a chemotherapeutic target. To address the proverbial “elephant in the room” as to whether MTH1 is a bona fide chemotherapeutic target, we provide an overview of MTH1 function in the context of tumor biology, summarize the current literature on MTH1 inhibitors, and discuss the molecular contexts likely required for its efficacy as a therapeutic target.

AB - Many tumors sustain elevated levels of reactive oxygen species (ROS), which drive oncogenic signaling. However, ROS can also trigger anti-tumor responses, such as cell death or senescence, through induction of oxidative stress and concomitant DNA damage. To circumvent the adverse consequences of elevated ROS levels, many tumors develop adaptive responses, such as enhanced redox-protective or oxidatively-generated damage repair pathways. Targeting these enhanced oxidative stress-protective mechanisms is likely to be both therapeutically effective and highly specific to cancer, as normal cells are less reliant on such mechanisms. In this review, we discuss one such stress-protective protein human MutT Homolog1 (MTH1), an enzyme that eliminates 8-oxo-7,8-dihydro-2’-deoxyguanosine triphosphate (8-oxodGTP) through its pyrophosphatase activity, and is found to be elevated in many cancers. Our studies, and subsequently those of others, identified MTH1 inhibition as an effective tumor-suppressive strategy. However, recent studies with the first wave of MTH1 inhibitors have produced conflicting results regarding their cytotoxicity in cancer cells and have led to questions regarding the validity of MTH1 as a chemotherapeutic target. To address the proverbial “elephant in the room” as to whether MTH1 is a bona fide chemotherapeutic target, we provide an overview of MTH1 function in the context of tumor biology, summarize the current literature on MTH1 inhibitors, and discuss the molecular contexts likely required for its efficacy as a therapeutic target.

KW - Cancer

KW - MTH1

KW - MTH1 inhibitors

KW - Nucleotide pool

KW - Oxidative stress

KW - P53

KW - RAS oncogene

KW - Therapeutic target

UR - http://www.scopus.com/inward/record.url?scp=85019141573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019141573&partnerID=8YFLogxK

U2 - 10.3390/cancers9050047

DO - 10.3390/cancers9050047

M3 - Review article

AN - SCOPUS:85019141573

VL - 9

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 5

M1 - 47

ER -